Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Piacentini

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
ESMO Open|October 11, 2025
Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trialM V Dieci, G Bisagni, S Bartolini, et al.
ESMO Open|December 20, 2024
Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept studyF Miglietta, A Collesei, C Vernieri, et al.
ESMO Open|January 5, 2021
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)B Pellegrino, L Cavanna, D Boggiani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2019
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancerM V Dieci, P Conte, G Bisagni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2025
A-BRAVE trial: a Phase 3 randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patientsP F Conte, M V Dieci, G Bisagni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2018
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡P Conte, A Frassoldati, G Bisagni, et al.
Physical Review Letters|May 1, 2001
Cosmology from MAXIMA-1, BOOMERANG, and COBE DMR cosmic microwave background observationsA H Jaffe, P A Ade, A Balbi, et al.
Physical Review Letters|March 28, 2015
Joint analysis of BICEP2/keck array and Planck DataP A R Ade, N Aghanim, Z Ahmed, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
ESMO Open|October 11, 2025
Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trialM V Dieci, G Bisagni, S Bartolini, et al.
ESMO Open|December 20, 2024
Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept studyF Miglietta, A Collesei, C Vernieri, et al.
ESMO Open|January 5, 2021
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)B Pellegrino, L Cavanna, D Boggiani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2019
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancerM V Dieci, P Conte, G Bisagni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2025
A-BRAVE trial: a Phase 3 randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patientsP F Conte, M V Dieci, G Bisagni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2018
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡P Conte, A Frassoldati, G Bisagni, et al.
Physical Review Letters|May 1, 2001
Cosmology from MAXIMA-1, BOOMERANG, and COBE DMR cosmic microwave background observationsA H Jaffe, P A Ade, A Balbi, et al.
Physical Review Letters|March 28, 2015
Joint analysis of BICEP2/keck array and Planck DataP A R Ade, N Aghanim, Z Ahmed, et al.
Pageof 7